Making Cancer Care Smarter
As the world's leading provider of genomic-based diagnostic tests, we're committed to making cancer care smarter with our Oncotype IQ Genomic Intelligence Platform. This expanding suite of tissue- and liquid-based tests answers specific questions across the patient journey—from diagnosis through treatment and ongoing cancer management-through a single, trusted source easily accessed via our secure web-based platform for physicians to interpret and share results with patients.
Oncology and Urology Channels
Our flagship line of gene expression tests has been used to guide treatment decisions for more than 800,000 breast, colon, and prostate cancer patients worldwide.
A liquid biopsy tumor mutation panel that uses next-generation sequencing to identify select genomic alterations for the treatment of late-stage lung cancer. Learn more
Oncotype IQ Platform Evolution
Later this year, we are planning to launch a new liquid biopsy-based test, in collaboration agreement with Epic Sciences to help men with metastatic prostate cancer determine the most effective, life-sustaining therapy. Performed in Epic Science's CLIA-certified laboratory, the test will detect the expression of the androgen receptor protein (AR-V7) in the nucleus of circulating tumor cells. Learn more
The Road Ahead
Looking ahead, we will continue to expand our Oncotype IQ platform through internal development programs and strategic partnerships, all with the goal of making cancer care smarter.